Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2019

01-12-2019 | Hypoglycemia | Review article

Patient and physician preferences for type 2 diabetes medications: a systematic review

Authors: Mahdi Toroski, Abbas Kebriaeezadeh, Alireza Esteghamati, Ali Kazemi Karyani, Hadi Abbasian, Shekoufeh Nikfar

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2019

Login to get access

Abstract

Background

There are several treatments to cure type 2 diabetes (T2D) and every one of them has certain attributes which is lead patients and specialists to have different preferences and select power. Therefore, we did this systematic study to evaluate patients̓ and physicians̓ preferences for type 2 diabetes medications by extracting attributes of anti-diabetic medications and identifying their relative importance.

Methods

We searched the PubMed, Ovid, Web of science, Scopus and Embase databases for articles which have been published on or before May 8th, 2018(The start time of the search in our study was May 8th, 2018).

Results

The searches identified 3346 studies, of which 17 (from 2009 to 2017) were included in the final synthesis and 27 attributes of type 2 anti-diabetic have been investigated. The most important attributes are changes of blood glucose and HbA1c level, hypoglycemia events, weight changes, gastrointestinal complications, cardiovascular effects, medicines cost, and administration mode and dosage of medicines.

Conclusion

physicians and patients prefer antidiabetics which is reduce blood glucose and HbA1c level effectively and have low side effects too (hypoglycemic event, cardiovascular and gastrointestinal). The effect of weight reduction, low cost, low dosing and low frequency of using. Health care providers, Specialist, and manufacturers should consider to these attributes in treatment process and marketing. It can increase adherence to management approaches, and reduce morbidity of patients with type 2 diabetes.
Literature
1.
go back to reference Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–83.PubMedCrossRef Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–83.PubMedCrossRef
2.
go back to reference García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.PubMedPubMedCentralCrossRef García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.PubMedPubMedCentralCrossRef
3.
go back to reference Wabe NT, Angamo MT, Hussein S. Medication adherence in diabetes mellitus and self management practices among type-2 diabetics in Ethiopia. N Am J Med Sci. 2011;3(9):418.PubMedPubMedCentralCrossRef Wabe NT, Angamo MT, Hussein S. Medication adherence in diabetes mellitus and self management practices among type-2 diabetics in Ethiopia. N Am J Med Sci. 2011;3(9):418.PubMedPubMedCentralCrossRef
4.
go back to reference Kassahun A, Gashe F, Mulisa E, Rike WA. Nonadherence and factors affecting adherence of diabetic patients to anti-diabetic medication in Assela general hospital, Oromia region, Ethiopia. J Pharm Bioall Sci. 2016;8(2):124–9.CrossRef Kassahun A, Gashe F, Mulisa E, Rike WA. Nonadherence and factors affecting adherence of diabetic patients to anti-diabetic medication in Assela general hospital, Oromia region, Ethiopia. J Pharm Bioall Sci. 2016;8(2):124–9.CrossRef
5.
go back to reference Habte BM, Kebede T, Fenta TG, Boon H. Barriers and facilitators to adherence to anti-diabetic medications: Ethiopian patients' perspectives. African PHCFM. 2017;9(1):1–9.CrossRef Habte BM, Kebede T, Fenta TG, Boon H. Barriers and facilitators to adherence to anti-diabetic medications: Ethiopian patients' perspectives. African PHCFM. 2017;9(1):1–9.CrossRef
6.
go back to reference Association AD. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S73–85.CrossRef Association AD. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S73–85.CrossRef
7.
go back to reference Mühlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making? Applied Health Economics and Health Policy. 2013;11(3):163–80.PubMedCrossRef Mühlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making? Applied Health Economics and Health Policy. 2013;11(3):163–80.PubMedCrossRef
8.
go back to reference Johnson FR, Hauber B, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm. 2010;16(8):616–28.PubMedCrossRef Johnson FR, Hauber B, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm. 2010;16(8):616–28.PubMedCrossRef
9.
go back to reference Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, et al. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care. 2009;25(3):359–66.PubMedCrossRef Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, et al. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care. 2009;25(3):359–66.PubMedCrossRef
10.
go back to reference Feher MD, Brazier J, Schaper N, Vega-Hernandez G, Nikolajsen A, Bøgelund M. Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes. BMJ Open Diabetes Res Care. 2016;4(1):e000192.PubMedPubMedCentralCrossRef Feher MD, Brazier J, Schaper N, Vega-Hernandez G, Nikolajsen A, Bøgelund M. Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes. BMJ Open Diabetes Res Care. 2016;4(1):e000192.PubMedPubMedCentralCrossRef
11.
go back to reference Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, et al. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. DRC. 2013;4(2):443–59.PubMedPubMedCentralCrossRef Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, et al. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. DRC. 2013;4(2):443–59.PubMedPubMedCentralCrossRef
12.
go back to reference Mark TL, Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. Health Econ. 2004;13(6):563–73.PubMedCrossRef Mark TL, Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. Health Econ. 2004;13(6):563–73.PubMedCrossRef
13.
go back to reference Discrete Choice Experiment (DCE) [online]. 2016. Discrete Choice Experiment (DCE) [online]. 2016.
14.
go back to reference Scott A. Identifying and analysing dominant preferences in discrete choice experiments: an application in health care. J Econ Psychol. 2002;23(3):383–98.CrossRef Scott A. Identifying and analysing dominant preferences in discrete choice experiments: an application in health care. J Econ Psychol. 2002;23(3):383–98.CrossRef
15.
go back to reference Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark–a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–83.PubMedCrossRef Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark–a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–83.PubMedCrossRef
16.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
17.
go back to reference Beelmann A. Review of systematic reviews in the social sciences: A practical guide. European Psychologist.2006;11(3):244–245. Beelmann A. Review of systematic reviews in the social sciences: A practical guide. European Psychologist.2006;11(3):244–245.
18.
go back to reference Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458.PubMedPubMedCentralCrossRef Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458.PubMedPubMedCentralCrossRef
19.
go back to reference Porzsolt F, Clouth J, Deutschmann M, Hippler H-J. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes. 2010;8(1):125.PubMedPubMedCentralCrossRef Porzsolt F, Clouth J, Deutschmann M, Hippler H-J. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes. 2010;8(1):125.PubMedPubMedCentralCrossRef
20.
go back to reference Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, et al. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017;8(6):1365–78.PubMedPubMedCentralCrossRef Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, et al. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017;8(6):1365–78.PubMedPubMedCentralCrossRef
21.
go back to reference Mühlbacher A, Bethge S. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur J Health Econ. 2016;17(9):1125–40.PubMedCrossRef Mühlbacher A, Bethge S. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur J Health Econ. 2016;17(9):1125–40.PubMedCrossRef
22.
go back to reference Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, Rodrigues J, et al. Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference Adher. 2015;9:1443. Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, Rodrigues J, et al. Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference Adher. 2015;9:1443.
23.
go back to reference Gelhorn H, Stringer S, Brooks A, Thompson C, Monz B, Boye K, et al. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes Obes Metab. 2013;15(9):802–9.PubMedCrossRef Gelhorn H, Stringer S, Brooks A, Thompson C, Monz B, Boye K, et al. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes Obes Metab. 2013;15(9):802–9.PubMedCrossRef
24.
go back to reference Mohamed A, Zhang J, Johnson F, Lomon ID, Malvolti E, Townsend R, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397–403.PubMedCrossRef Mohamed A, Zhang J, Johnson F, Lomon ID, Malvolti E, Townsend R, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397–403.PubMedCrossRef
25.
go back to reference Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–67.PubMedCrossRef Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–67.PubMedCrossRef
26.
go back to reference Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson Å, Bøgelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–23.PubMedCrossRef Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson Å, Bøgelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–23.PubMedCrossRef
27.
go back to reference Hauber A, Mohamed A, Johnson F, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24.PubMedCrossRef Hauber A, Mohamed A, Johnson F, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24.PubMedCrossRef
28.
go back to reference Flood EM, Bell KF, de la Cruz MC, Ginchereau-Sowell FM. Patient preferences for diabetes treatment attributes and drug classes. Curr Med Res Opin. 2017;33(2):261–8.PubMedCrossRef Flood EM, Bell KF, de la Cruz MC, Ginchereau-Sowell FM. Patient preferences for diabetes treatment attributes and drug classes. Curr Med Res Opin. 2017;33(2):261–8.PubMedCrossRef
29.
go back to reference Hauber AB, Tunceli K, Yang J-C, Gantz I, Brodovicz KG, Alexander CM, et al. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Therapy. 2015;6(1):75–84.PubMedPubMedCentralCrossRef Hauber AB, Tunceli K, Yang J-C, Gantz I, Brodovicz KG, Alexander CM, et al. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Therapy. 2015;6(1):75–84.PubMedPubMedCentralCrossRef
30.
go back to reference Hauber AB, Nguyen H, Posner J, Kalsekar I, Ruggles J. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2016;32(2):251–62.PubMedCrossRef Hauber AB, Nguyen H, Posner J, Kalsekar I, Ruggles J. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2016;32(2):251–62.PubMedCrossRef
31.
go back to reference Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products–liraglutide and exenatide–for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.PubMedCrossRef Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products–liraglutide and exenatide–for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.PubMedCrossRef
32.
go back to reference Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. 2018;61(12):2461–98.PubMedCrossRef Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. 2018;61(12):2461–98.PubMedCrossRef
33.
go back to reference Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–5.PubMedCrossRef Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–5.PubMedCrossRef
34.
go back to reference van Wijngaarden RP, Overbeek JA, Heintjes EM, Schubert A, Diels J, Straatman H, et al. Relation between different measures of glycemic exposure and microvascular and macrovascular complications in patients with type 2 diabetes mellitus: an observational cohort study. Diabetes Ther. 2017;8(5):1097–109.PubMedPubMedCentralCrossRef van Wijngaarden RP, Overbeek JA, Heintjes EM, Schubert A, Diels J, Straatman H, et al. Relation between different measures of glycemic exposure and microvascular and macrovascular complications in patients with type 2 diabetes mellitus: an observational cohort study. Diabetes Ther. 2017;8(5):1097–109.PubMedPubMedCentralCrossRef
35.
go back to reference Larkin AT, Hoffman C, Stevens A, Douglas A, Bloomgarden Z. Determinants of adherence to diabetes treatment. J Diabetes. 2015;7(6):864–71.PubMedCrossRef Larkin AT, Hoffman C, Stevens A, Douglas A, Bloomgarden Z. Determinants of adherence to diabetes treatment. J Diabetes. 2015;7(6):864–71.PubMedCrossRef
36.
go back to reference Misra A, Tandon N, Ebrahim S, Sattar N, Alam D, Shrivastava U, et al. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ (British medical journal). 2017;357:j1420.CrossRef Misra A, Tandon N, Ebrahim S, Sattar N, Alam D, Shrivastava U, et al. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ (British medical journal). 2017;357:j1420.CrossRef
37.
go back to reference Bray GA. Medical consequences of obesity. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2583–9.CrossRef Bray GA. Medical consequences of obesity. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2583–9.CrossRef
38.
40.
go back to reference Matza LS, Yurgin N, Boye KS, Malley K, Shorr JM. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051–62.PubMedCrossRef Matza LS, Yurgin N, Boye KS, Malley K, Shorr JM. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051–62.PubMedCrossRef
41.
go back to reference Alsahli M, Gerich JE. Hypoglycemia. Endocrinology and metabolism clinics of North America. 2013;42(4):657–76.PubMedCrossRef Alsahli M, Gerich JE. Hypoglycemia. Endocrinology and metabolism clinics of North America. 2013;42(4):657–76.PubMedCrossRef
42.
go back to reference Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. JDMD (journal of diabetes & metabolic disorders). 2012;11(1):17. Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. JDMD (journal of diabetes & metabolic disorders). 2012;11(1):17.
43.
go back to reference Ortiz MR. Hypoglycemia in Diabetes. The Nursing clinics of North America. 2017;52(4):565–74.CrossRef Ortiz MR. Hypoglycemia in Diabetes. The Nursing clinics of North America. 2017;52(4):565–74.CrossRef
44.
45.
go back to reference Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620–9.PubMedPubMedCentralCrossRef Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620–9.PubMedPubMedCentralCrossRef
46.
go back to reference Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endo. 2017;5(6):423–30.CrossRef Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endo. 2017;5(6):423–30.CrossRef
47.
go back to reference Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.PubMedCrossRef Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.PubMedCrossRef
48.
go back to reference Lazaro A, Barberan R, Rubio E. Private and social time preferences for health and money: an empirical estimation. Health Econ. 2001;10(4):351–6.PubMedCrossRef Lazaro A, Barberan R, Rubio E. Private and social time preferences for health and money: an empirical estimation. Health Econ. 2001;10(4):351–6.PubMedCrossRef
49.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015;38(1):140–9.CrossRef Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015;38(1):140–9.CrossRef
50.
go back to reference Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.PubMedCrossRef Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.PubMedCrossRef
Metadata
Title
Patient and physician preferences for type 2 diabetes medications: a systematic review
Authors
Mahdi Toroski
Abbas Kebriaeezadeh
Alireza Esteghamati
Ali Kazemi Karyani
Hadi Abbasian
Shekoufeh Nikfar
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2019
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00449-4

Other articles of this Issue 2/2019

Journal of Diabetes & Metabolic Disorders 2/2019 Go to the issue